InvaGen Pharma Clears FDA GMP Inspection With Single Form 483 Observation

Cipla's US generics unit exits routine USFDA audit with one minor finding; no Warning Letter or import alert issued, suggesting minimal regulatory disruption ahead.

ndtv-profit-business · 7/18/2026, 8:02:29 AM · Ask about this →